Fulcrum Therapeutics Inc (FULC) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Fulcrum Therapeutics Inc in the second quarter 2026?
Fulcrum Therapeutics Inc recorded a cumulative net loss of $-85 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -28.54%.
Within the Major Pharmaceutical Preparations industry 113 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2702 to 2986.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a prominent player in the biopharmaceutical industry, is currently under investigation by Bronstein, Gewirtz and Grossman, LLC. This development has sent ripples of concern through the investor community, with many seeking to understand the underlying causes and potential implications of this scrutiny.Bronstein, Gewirtz and Grossman, LLC, a well-known firm specializing in shareholder rights, recently announced its investigation into potential claims on behalf of purchasers of Fulcrum Therapeutics securities. On September 13, 2024, the firm initially disclosed its intent to probe the activities of Fulcrum Therapeutics, urging investors who purchased securities to visit their website to gather more information and assist with the investigation. The firm reiterated this call to action on September 25, 2024, signaling the importance and urgency of the matter.
: The pharmaceutical sector is often characterized by rapid fluctuations in stock prices, driven by a multitude of factors including clinical trial outcomes, regulatory developments, and market dynamics. Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a company focused on advancing precision medicine for patients with genetically-driven diseases, has recently become the subject of scrutiny following announcements by Bronstein, Gewirtz and Grossman, LLC. This piece examines the implications of the firm’s investigation, the current valuation of Fulcrum Therapeutics, the broader context of pharmaceutical investments, and the potential ramifications for stakeholders in the industry.The recent alert from Bronstein, Gewirtz and Grossman, LLC concerning Fulcrum Therapeutics, Inc. presents an important juncture for stakeholders in the biotech and pharmaceutical space. As of September 19, 2024, Fulcrum has garnered attention due to an ongoing investigation into potential claims that may affect its stock performance. With 61.58 million shares outstanding and a stock price of $3.36, the Company is situated within a dynamic and uncertain market environment that necessitates close examination from both legal and financial perspectives.
nnFulcrum Therapeutics Reports Disappointing Phase 3 Results for Losmapimod in FSHD: Financial Ramifications and Stock Performance Analysisnn Fulcrum Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare genetic disorders, recently disclosed top-line results from its Phase 3 REACH clinical trial assessing the efficacy of losmapimod for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Unfortunately, the trial outcomes fell below expectations, as losmapimod did not demonstrate significant improvement in relative surface area (RSA)—a critical measure of reachable workspace (RWS)—when compared to a placebo at the 48-week mark. This disappointing announcement comes as a setback for Fulcrum Therapeutics, which has been strategically positioning itself within the biopharmaceutical landscape. The failure of losmapimod to deliver expected clinical results not only impacts its immediate revenue potential but also sends ripples through investor confidence. The company’s stock, currently trading at $8.79 per share—21.4% above its 52-week average—may experience volatility as stakeholders reassess the prospects of losmapimod and its broader portfolio.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
